GW Pharmaceuticals to Present at Bank of America Merrill Lynch 2018 Health Care Conference
May 08, 2018 13:00 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and...
GW Pharmaceuticals to Report Second Quarter Financial Results and Host Conference Call on 8 May, 2018
May 03, 2018 07:37 ET
|
GW Pharmaceuticals plc
LONDON, May 03, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel...
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announces the Unanimous Positive Result of FDA Advisory Committee Meeting for First Plant-Based Pharmaceutical Cannabidiol Treatment for Seizures in Patients with Two Rare, Severe Forms of Epilepsy
April 19, 2018 12:45 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW”, “the Company” or “the Group”), a biopharmaceutical company focused on discovering,...
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol oral solution) at the 2018 American Academy of Neurology Annual Meeting
April 12, 2018 07:00 ET
|
GW Pharmaceuticals plc
LONDON, April 12, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and...
GW Pharmaceuticals Announces Receipt of Notices of Allowance by the United States Patent and Trademark Office (USPTO) for Five New Epidiolex® (cannabidiol) Patents
March 13, 2018 16:01 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., March 13, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering,...
GW Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference on 12 March
March 05, 2018 12:36 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing...
GW Pharmaceuticals Receives Orphan Drug Designation from the European Medicines Agency (EMA) for Cannabidiol for the Treatment of Tuberous Sclerosis
February 27, 2018 07:00 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering,...
GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006
February 21, 2018 16:01 ET
|
GW Pharmaceuticals plc
-Study did not meet its primary endpoint- -Company remains committed to continued development of GWP42006 for autism spectrum disorders and will continue to explore the product’s potential within the...
GW Pharmaceuticals to Present at the Leerink Partners 7th Annual Global Healthcare Conference on 14 February
February 06, 2018 11:35 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Feb. 06, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and...
GW Pharmaceuticals plc Reports Fiscal First Quarter 2018 Financial Results and Operational Progress
February 05, 2018 16:00 ET
|
GW Pharmaceuticals plc
- Epidiolex® (cannabidiol) NDA and MAA applications accepted for review –- NDA PDUFA goal date scheduled for June 27, 2018 -- Conference call today at 4:30 p.m. EST - LONDON and CARLSBAD, Calif.,...